Phone: (919) 843-7683
Fax: (919) 966-8994
B.A., Johns Hopkins University
M.D., Wake Forest University School of Medicine
Residency, Psychiatry, University of North Carolina Hospitals
Fellowship, Psychiatry Research, University of North Carolina at Chapel Hill
Dr. Jarskog’s research is focused on the pathophysiology and treatment of schizophrenia. He conducts clinical trials for patients with schizophrenia, testing drugs with novel mechanisms of action, with a particular focus on treatments for cognitive impairment and for weight gain and metabolic deficits associated with antipsychotic drugs. He also studies factors that help regulate neuronal viability, such as neurotrophins (e.g BDNF) and apoptotic regulatory proteins (e.g. Bcl-2), and how these may contribute to the neuropathology of schizophrenia.
1. Miyake N, Miyamoto S, Jarskog LF. New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress? In press, Clin Schizophr Relat Psychoses.
2. Javitt DC, Buchanan RW, Keefe RSE, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res. 2012 136:25-31.
3. Kayser J, Tenke CE, Kroppmann CJ, Alschuler DM, Fekri S, Gil R, Jarskog LF, Harkavy-Friedman JM, Bruder GE. A Neurophysiological Deficit in Early Visual Processing in Schizophrenia Patients with Auditory Hallucinations. Psychophysiol. 2012 49:1168-1178.
4. Buchanan RW, Keefe RSE, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry. 2011;69:442-449.
5. Glantz LA, Gilmore JH, Overstreet DH, Salimi K, Lieberman JA, Jarskog LF. Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophr Res. 2010;118:292-299.